Weldon Ryan 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Mar 6, 2013
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Award
Non-Qualified Stock (rights to purchase)
2013-03-05+13,700→ 13,700 totalExercise: $69.41From: 2017-03-05Exp: 2023-03-05→ Common Shares, no par value (13,700 underlying) - Award
Restricted Share Units
2013-01-28+11,000→ 11,000 totalExercise: $0.00→ Common Shares, no par value (11,000 underlying)
Footnotes (3)
- [F1]The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
- [F2]Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3).
- [F3]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $62.62 on each of three measurement dates: 25% would vest on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016, with early vesting possible at higher TSR levels.